Aua Capital Management LLC Reduces Stock Position in Boston Scientific Co. (NYSE:BSX)

Aua Capital Management LLC cut its stake in Boston Scientific Co. (NYSE:BSX) by 30.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,045 shares of the medical equipment provider’s stock after selling 2,694 shares during the period. Aua Capital Management LLC’s holdings in Boston Scientific were worth $327,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Boston Scientific by 1.9% during the 1st quarter. Geode Capital Management LLC now owns 25,329,129 shares of the medical equipment provider’s stock worth $1,263,857,000 after purchasing an additional 473,888 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Boston Scientific by 7.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 23,393,853 shares of the medical equipment provider’s stock worth $1,082,436,000 after acquiring an additional 1,659,431 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its position in Boston Scientific by 112,306.1% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 18,661,660 shares of the medical equipment provider’s stock worth $863,475,000 after acquiring an additional 18,645,058 shares during the last quarter. Northern Trust Corp boosted its position in Boston Scientific by 0.3% during the first quarter. Northern Trust Corp now owns 13,867,256 shares of the medical equipment provider’s stock worth $614,181,000 after acquiring an additional 45,404 shares during the last quarter. Finally, Norges Bank acquired a new stake in Boston Scientific during the fourth quarter worth approximately $632,520,000. 89.11% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 6,697 shares of the company’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $53.80, for a total value of $360,298.60. Following the completion of the sale, the executive vice president now owns 17,453 shares in the company, valued at approximately $938,971.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 11,671 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $52.85, for a total value of $616,812.35. Following the completion of the sale, the executive vice president now owns 67,584 shares in the company, valued at approximately $3,571,814.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 6,697 shares of the stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $53.80, for a total transaction of $360,298.60. Following the transaction, the executive vice president now owns 17,453 shares in the company, valued at approximately $938,971.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 208,465 shares of company stock worth $11,053,789. 0.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on BSX shares. Citigroup restated a “buy” rating and set a $63.00 target price on shares of Boston Scientific in a research report on Monday, August 28th. Truist Financial boosted their price objective on shares of Boston Scientific from $60.00 to $61.00 in a research note on Wednesday, July 19th. Oppenheimer boosted their price objective on shares of Boston Scientific from $58.00 to $59.00 in a research note on Friday, July 28th. Barclays boosted their price objective on shares of Boston Scientific from $56.00 to $59.00 and gave the company an “overweight” rating in a research note on Monday, July 31st. Finally, Robert W. Baird started coverage on shares of Boston Scientific in a research report on Tuesday, July 18th. They set an “outperform” rating and a $59.00 price target for the company. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $58.50.

Boston Scientific Stock Up 0.8 %

Shares of Boston Scientific stock traded up $0.43 during trading on Monday, reaching $53.33. The company had a trading volume of 485,970 shares, compared to its average volume of 7,974,393. The firm’s fifty day moving average is $52.26 and its 200-day moving average is $51.62. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.80 and a current ratio of 1.29. The company has a market cap of $78.09 billion, a price-to-earnings ratio of 87.60, a price-to-earnings-growth ratio of 2.09 and a beta of 0.78. Boston Scientific Co. has a fifty-two week low of $37.74 and a fifty-two week high of $54.99.

Boston Scientific (NYSE:BSX) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.04. The firm had revenue of $3.60 billion during the quarter, compared to analysts’ expectations of $3.50 billion. Boston Scientific had a net margin of 6.81% and a return on equity of 15.16%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.44 earnings per share. On average, analysts anticipate that Boston Scientific Co. will post 1.99 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.